Key Performance
More- Earnings Score: 86
- Momentum Score: 33
- True Yield: N/A
- Financial Health Score: 62
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The FTC filed a lawsuit against Hims & Hers Health, Inc. on July 29, 2026, alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms while claiming to maintain privacy, and deceived users about billing and cancellation practices. The stock declined 14.73% on the news. A class action lawsuit has been filed for investors who purchased HIMS securities between August 4, 2025 and July 29, 2026, with a November 2, 2026 deadline to file a lead plaintiff motion.
09/09/2026, 2:45 PM • GlobeNewswire
Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Wix.com, Hertz Global Holdings, and Hims & Hers Health on behalf of investors who suffered losses. The Wix lawsuit covers investors from February 19, 2025 to May 12, 2026, alleging the company misrepresented its AI capabilities while costs accelerated. Wix's stock fell 27.1% following disappointing Q1 2026 results. Investors with losses are encouraged to contact the firm before respective deadlines.
09/08/2026, 12:58 PM • GlobeNewswire
A class action lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud. The complaint claims the company made false statements about sharing consumer health information with third-party advertisers, charging for prescriptions immediately despite promising consultations, and failing to disclose regulatory scrutiny and potential penalties. Investors who purchased Hims securities between August 4, 2025 and July 29, 2026 may be eligible to join the case.
09/07/2026, 12:00 PM • GlobeNewswire
Rosen Law Firm has filed a class action lawsuit on behalf of Hims & Hers Health, Inc. investors for the period between August 4, 2025 and July 29, 2026. The lawsuit alleges that Hims made materially false and misleading statements regarding consumer health data sharing with third-party advertisers, premature prescription charges despite promised consultations, and undisclosed regulatory scrutiny and potential penalties. Investors who purchased securities during the class period may be eligible for compensation.
09/04/2026, 3:38 PM • GlobeNewswire
Kaplan Fox has filed class action lawsuits against three companies: Hims & Hers for allegedly failing to disclose immediate prescription charges, sharing health data with third parties, and making subscription cancellations difficult; Hyliion Holdings for undisclosed issues during May-June 2026; and Innventure for regulatory concerns from November 2025 to August 2026. Investors with losses are encouraged to contact the firm before respective deadlines.
09/04/2026, 1:45 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS) for allegedly making material misstatements about its privacy practices. The FTC accused HIMS of sharing customers' medical information with third-party advertisers including Meta and Snap, and charging consumers for prescriptions immediately despite promising consultation with medical providers. The stock declined 14.73% on the news. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 can seek lead plaintiff status by November 2, 2026.
09/04/2026, 1:41 PM • GlobeNewswire
A securities fraud class action lawsuit has been filed against Hims & Hers Health, Inc. following an FTC lawsuit alleging the telehealth provider shared consumers' sensitive health information with third-party advertising platforms and engaged in deceptive billing practices. The stock declined 14.73% on the news. Investors who purchased HIMS securities between August 4, 2025 and July 29, 2026 have until November 2, 2026 to file a lead plaintiff motion.
09/03/2026, 9:00 AM • GlobeNewswire
Hims & Hers Health (NYSE: HIMS) faces a securities class action lawsuit following an FTC complaint alleging the company engaged in deceptive health data sharing with advertising platforms like Meta and Snap, and violated billing regulations by charging consumers for prescriptions before medical consultations. The lawsuit, filed by the FTC alongside Utah and Los Angeles County, also accuses Hims of using dark patterns to prevent subscription cancellations. The stock dropped 14.7% ($4.32) on July 29, 2026, erasing over $970 million in market value.
09/02/2026, 5:34 PM • GlobeNewswire
A securities class action lawsuit has been filed against Hims & Hers Health, Inc. for the period between August 4, 2025 and July 29, 2026. The FTC sued the company for failing to disclose immediate prescription charges, making subscription cancellations difficult, and sharing consumer health information with third-party advertising platforms like Meta and Snap. The stock fell 14.73% following the FTC allegations. The lead plaintiff deadline is November 2, 2026.
09/02/2026, 1:43 PM • GlobeNewswire
Hims & Hers Health, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into possible securities fraud against Hims & Hers Health, Inc., alleging the telehealth platform deceived consumers by charging them for unwanted prescription medication subscriptions without express informed consent. The company's advertising and intake forms allegedly misrepresented that consultations were free and created no purchase obligation. Following public disclosures of these deceptive practices, Hims stock fell sharply, causing significant investor losses.
08/25/2026, 2:57 PM • GlobeNewswire
An Insider at Hims & Hers Just Filed. Here's What It Says About Buying the Dip
Hims & Hers' Chief Legal Officer Soleil Boughton sold 21,500 shares (~$605,000) on August 14 through a non-discretionary tax withholding transaction, retaining 339,075 shares. The sale does not reflect a shift in the insider's assessment of the company. Despite the stock's -40% one-year return, the underlying business shows strength with 38% revenue growth to $753.2 million last quarter and raised full-year guidance to $3.1-$3.3 billion. However, an FTC lawsuit over data sharing and billing practices creates uncertainty, with a $47.5 million legal contingency already impacting earnings.
08/19/2026, 5:29 AM • The Motley Fool
What Long-Term Investors Should Know About This Hims Insider Filing
Hims & Hers Chief Operating Officer Michael Chi sold 47,702 shares worth $1.3 million on August 14, but this was a non-discretionary tax withholding tied to quarterly RSU vesting, not an active investment decision. Chi retains 470,687 shares and has nearly 600,000 RSUs vesting through June 2029, indicating confidence in the company's future. The sale reflects Chi's focus on managing the company's aggressive expansion, including the major Eucalyptus acquisition and international growth targeting $600 million in 2026 revenue.
08/19/2026, 5:21 AM • The Motley Fool
Chief Medical Officer Patrick Harrison Carroll sold 10,201 shares of Hims & Hers Health (HIMS) worth $287,158 on August 14 due to routine tax withholding obligations from RSU vesting. The sale is non-discretionary and does not reflect insider sentiment. The company is expanding into new specialties like testosterone replacement therapy, which is approaching $100 million in annual run rate, though this expansion may compress gross margins.
08/19/2026, 5:11 AM • The Motley Fool
The Federal Trade Commission filed a lawsuit against Hims & Hers Health, Inc. on July 29, 2026, alleging the company engaged in deceptive privacy practices by sharing customers' sensitive medical information with third-party advertisers including Meta Platforms and Snap. Following the lawsuit announcement, HIMS stock price fell over 14%. A securities litigation law firm is investigating potential federal securities law violations on behalf of affected investors.
08/09/2026, 5:22 PM • GlobeNewswire
Law firm Kirby McInerney LLP is investigating Hims & Hers Health following an FTC lawsuit alleging the company engaged in deceptive privacy practices by sharing customers' sensitive medical information with third-party advertisers including Meta Platforms. The announcement triggered a 14.73% stock price decline on July 29, 2026.
08/05/2026, 8:00 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 09/11/2026
Company Profile
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.